Genotoxicity testing of low molecular weight fucoidan from brown seaweeds

Song, Moon Yong; Ku, Sae Kwang; Han, Jin Soo

doi:10.1016/j.fct.2011.11.010

Cited by 37 publications

(32 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the fact that LMWF possesses additional beneficial effects such as inhibiting platelet aggregation and improving endothelium relaxation with higher safety profile (Cui et al, 2014;Li et al, 2005;Song et al, 2012;Yoon et al, 2009;Yoon et al, 2010), this study provides the evidence of LMWF as a potential adjuvant drug to treat type 1 diabetic complications.…”

Section: Discussionmentioning

confidence: 91%

“…LMWF, an extract from natural occurring brown algae, has been shown to have favorable toxic profile, and it has been demonstrated that 2000 mg/kg oral gavage of LMWF in mice or rats showed no significant toxicity (Song et al, 2012;Yoon et al, 2009;Yoon et al, 2010). In previous studies, we compared two preparations of fucoidans (6.5 kDa and 120 kDa) extracted from Laminaria japonica Areschoug in Rongcheng as well as the fucoidan (50 kDa) purchased from Sigma Aldrich, and found LMWF (6.5 kDa) exhibited antithrombotic property without effect on coagulation, and the other fucoidans more or less decreased coagulation at the dose inhibiting platelet aggregation (Cui et al, 2014).…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Low molecular weight fucoidan ameliorates streptozotocin-induced hyper-responsiveness of aortic smooth muscles in type 1 diabetes rats

Liang

Zheng

Wang

et al. 2016

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 96%

Low molecular weight fucoidan ameliorates streptozotocin-induced hyper-responsiveness of aortic smooth muscles in type 1 diabetes rats

Liang

Zheng

Wang

et al. 2016

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…Fucoidan does not show toxicity in vitro and in vivo 39. It was reported that the dose of LMWF up to 2000 mg/kg body weight in mice is safe and has no significant genotoxic concern40.…”

Section: Discussionmentioning

confidence: 98%

Low molecular weight fucoidan protects renal tubular cells from injury induced by albumin overload

Jia

Sun

Weng

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Albuminuria is a causative and aggravating factor for progressive renal damage in chronic kidney disease (CKD). The aim of this study was to determine if low molecular weight fucoidan (LMWF) could protect renal function and tubular cells from albumin overload caused injury. Treatment with 10 mg/g bovine serum albumin caused renal dysfunction, morphological changes, and overexpression of inflammation and fibrosis associated proteins in 129S2/Sv mice. LMWF (100 mg/kg) protected against kidney injury and renal dysfunction with decreased blood creatinine by 34% and urea nitrogen by 25%, increased creatinine clearance by 48%, and decreased significantly urinary albumin concentration. In vitro proximal tubule epithelial cell (NRK-52E) model showed that LMWF dose-dependently inhibited overexpression of proinflammatory and profibrotic factors, oxidative stress and apoptosis caused by albumin overload. These experimental results indicate that LMWF protects against albumin overload caused renal injury by inhibiting inflammation, fibrosis, oxidative stress and apoptosis, which suggests that LMWF could be a promising candidate drug for preventing CKD.

show abstract

“…The use of low molecular weight fucoidan (<7 kDa) is currently thought to be safe up to 2000 mg/kg body weight per day in rats1819 and presents no significant genotoxic concern20. Fucoidan has been reported to have antiviral, antioxidant, antimicrobial, anticoagulant, antitumor, and anti-inflammatory properties21.…”

mentioning

confidence: 99%

Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway

Chen

Sue

Cheng

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Tubulointerstitial fibrosis is recognized as a key determinant of progressive chronic kidney disease (CKD). Fucoidan, a sulphated polysaccharide extracted from brown seaweed, exerts beneficial effects in some nephropathy models. The present study evaluated the inhibitory effect of oligo-fucoidan (800 Da) on renal tubulointerstitial fibrosis. We established a mouse CKD model by right nephrectomy with transient ischemic injury to the left kidney. Six weeks after the surgery, we fed the CKD mice oligo-fucoidan at 10, 20, and 100 mg/kg/d for 6 weeks and found that the oligo-fucoidan doses less than 100 mg/kg/d improved renal function and reduced renal tubulointerstitial fibrosis in CKD mice. Oligo-fucoidan also inhibited pressure-induced fibrotic responses and the expression of CD44, β-catenin, and TGF-β in rat renal tubular cells (NRK-52E). CD44 knockdown downregulated the expression of β-catenin and TGF-β in pressure-treated cells. Additional ligands for CD44 reduced the anti-fibrotic effect of oligo-fucoidan in NRK-52E cells. These data suggest that oligo-fucoidan at the particular dose prevents renal tubulointerstitial fibrosis in a CKD model. The anti-fibrotic effect of oligo-fucoidan may result from interfering with the interaction between CD44 and its extracellular ligands.

show abstract

Genotoxicity testing of low molecular weight fucoidan from brown seaweeds

Cited by 37 publications

References 34 publications

Low molecular weight fucoidan ameliorates streptozotocin-induced hyper-responsiveness of aortic smooth muscles in type 1 diabetes rats

Low molecular weight fucoidan ameliorates streptozotocin-induced hyper-responsiveness of aortic smooth muscles in type 1 diabetes rats

Low molecular weight fucoidan protects renal tubular cells from injury induced by albumin overload

Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway

Contact Info

Product

Resources

About